Market capitalisation: €309.6 million
Dublin – 17 July 2019 – Euronext Dublin today welcomes Uniphar, a diversified healthcare services group to Euronext Growth.
Headquartered in Dublin, Uniphar is a diversiﬁed international healthcare services business meeting the requirements of over 200 multinational pharmaceutical and medical technology manufacturers. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux. The Company’s vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders.
Uniphar (ticker code: UPR) was listed on 17 July 2019 through the admission to trading of 269.2m shares making up its capital. The listing price was set at €1.15per share. Market capitalisation on the day of listing was circa €309.6 million.
At this morning’s listing ceremony, Uniphar CEO Ger Rabbette said:
"Today marks a major milestone in Uniphar’s 50-year history. With a strong platform for growth in place in our two high growth divisions (Clinical & Commercial and Product Access), today’s listing on the Euronext Growth market will help fuel our strategy which will see us doubling EBITDA over the next five years. It will also allow us to attract new investors and capital from across Europe. I want to especially acknowledge the major contribution of a very talented team of people at Uniphar who have worked so hard to get us to this important point in our company’s development.”
CEO of Euronext Dublin, Daryl Byrne said:
“On behalf of Euronext, I would like to extend the warmest of welcomes and congratulations to the Uniphar team on this major milestone. The story of their growth and success is yet another fantastic example of Irish innovation in the pharmaceutical sector, and we look forward to celebrating the future successes that come from being a Euronext-listed company.”
Uniphar is a diversified healthcare services business with a workforce of over 2,000 employees servicing the requirements of more than 200 multinational pharmaceutical and medical device manufacturers across three divisions; Commercial & Clinical, Product Access and Supply Chain & Retail. Based in Citywest, Dublin, the company’s vision is to improve patient access to pharmacomedical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability. In 2018, the Group generated revenue of €1.55 billion, gross profit of €159.6 million and EBITDA of €46.3 million on a pro forma basis. The Group’s strategy is to double Group EBITDA over the 5-year period from 2019 – 2023 by focussing on meeting the needs of speciality manufacturers by:>
o Scaling existing and new relationships with manufacturers to provide integrated, insight driven, multi-channel solutionsfor speciality products.
o Building a pan-European infrastructure for pharmaco-medical sales and distribution in speciality areas, from an existing presence in Ireland, the UK and the Benelux with an intention to enter the Nordics in 2019.
o Leveraging the Group’s global footprint and in-house expertise to accelerate international growth in Product Access, directly for On-Demand Access in strategic markets, and on a global basis for Exclusive Access for speciality and orphan medicines.
o Managing an efficient and cash generative operating model in Supply Chain & Retail for reinvestment in the high growth divisions whilst maintaining a leading market position in Ireland.